Literature DB >> 34951700

Genomic analyses of the metastasis-derived prostate cancer cell lines LNCaP, VCaP, and PC3-AR.

Karolina Sienkiewicz1, Chunsong Yang2,3, Bryce M Paschal2,3, Aakrosh Ratan1,4.   

Abstract

BACKGROUND: The lymph node metastasis-derived LNCaP, the bone metastasis-derived PC3 (skull), and VCaP (vertebral) cell lines are widely used as preclinical models of human prostate cancer (CaP) and have been described in more than 19,000 publications. Here, we report on short-read whole-genome sequencing and genomic analyses of LNCaP, VCaP, and PC3 cells stably transduced with WT AR (PC3-AR).
METHODS: LNCaP, VCaP, and PC3-AR cell lines were sequenced to an average depth of more than 30-fold using Illumina short-read sequencing. Using various computational methods, we identified and compared the single-nucleotide variants, copy-number profiles, and the structural variants observed in the three cell lines.
RESULTS: LNCaP cells are composed of multiple subpopulations, which results in nonintegral copy number states and a high mutational load when the data is analyzed in bulk. All three cell lines contain pathogenic mutations and homozygous deletions in genes involved in DNA mismatch repair, along with deleterious mutations in cell-cycle, Wnt signaling, and other critical cellular processes. PC3-AR cells have a truncating mutation in TP53 and do not express the p53 protein. The VCaP cells contain a homozygous gain-of-function mutation in TP53 (p.R248W) that promotes cancer invasion, metastasis, and progression and has also been observed in prostate adenocarcinomas. In addition, we detect the signatures of chromothripsis of the q arms of chromosome 5 in both PC3-AR and VCaP cells, strengthening the association of TP53 inactivation with chromothripsis reported in other systems.
CONCLUSIONS: Our work provides a resource for genetic, genomic, and biological studies employing these commonly-used prostate cancer cell lines.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  CaP cell lines; chromothripsis; copy-number variants; fusions; pathogenic mutations

Mesh:

Year:  2021        PMID: 34951700      PMCID: PMC8792310          DOI: 10.1002/pros.24290

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  43 in total

Review 1.  Making heads or tails - the emergence of capicua (CIC) as an important multifunctional tumour suppressor.

Authors:  Derek Wong; Stephen Yip
Journal:  J Pathol       Date:  2020-03-04       Impact factor: 7.996

2.  Unified representation of genetic variants.

Authors:  Adrian Tan; Gonçalo R Abecasis; Hyun Min Kang
Journal:  Bioinformatics       Date:  2015-02-19       Impact factor: 6.937

3.  PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.

Authors:  Ivan V Litvinov; Lizamma Antony; Susan L Dalrymple; Robyn Becker; Linzhao Cheng; John T Isaacs
Journal:  Prostate       Date:  2006-09-01       Impact factor: 4.104

4.  VCaP, a cell-based model system of human prostate cancer.

Authors:  S Korenchuk; J E Lehr; L MClean; Y G Lee; S Whitney; R Vessella; D L Lin; K J Pienta
Journal:  In Vivo       Date:  2001 Mar-Apr       Impact factor: 2.155

5.  Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells.

Authors:  J L Dai; C A Maiorino; P J Gkonos; K L Burnstein
Journal:  Steroids       Date:  1996-09       Impact factor: 2.668

6.  Genetic variation in RNASEL and risk for prostate cancer in a population-based case-control study.

Authors:  Megan D Fesinmeyer; Erika M Kwon; Rong Fu; Elaine A Ostrander; Janet L Stanford
Journal:  Prostate       Date:  2011-02-25       Impact factor: 4.104

7.  Next-generation characterization of the Cancer Cell Line Encyclopedia.

Authors:  Mahmoud Ghandi; Franklin W Huang; Judit Jané-Valbuena; Gregory V Kryukov; Christopher C Lo; E Robert McDonald; Jordi Barretina; Ellen T Gelfand; Craig M Bielski; Haoxin Li; Kevin Hu; Alexander Y Andreev-Drakhlin; Jaegil Kim; Julian M Hess; Brian J Haas; François Aguet; Barbara A Weir; Michael V Rothberg; Brenton R Paolella; Michael S Lawrence; Rehan Akbani; Yiling Lu; Hong L Tiv; Prafulla C Gokhale; Antoine de Weck; Ali Amin Mansour; Coyin Oh; Juliann Shih; Kevin Hadi; Yanay Rosen; Jonathan Bistline; Kavitha Venkatesan; Anupama Reddy; Dmitriy Sonkin; Manway Liu; Joseph Lehar; Joshua M Korn; Dale A Porter; Michael D Jones; Javad Golji; Giordano Caponigro; Jordan E Taylor; Caitlin M Dunning; Amanda L Creech; Allison C Warren; James M McFarland; Mahdi Zamanighomi; Audrey Kauffmann; Nicolas Stransky; Marcin Imielinski; Yosef E Maruvka; Andrew D Cherniack; Aviad Tsherniak; Francisca Vazquez; Jacob D Jaffe; Andrew A Lane; David M Weinstock; Cory M Johannessen; Michael P Morrissey; Frank Stegmeier; Robert Schlegel; William C Hahn; Gad Getz; Gordon B Mills; Jesse S Boehm; Todd R Golub; Levi A Garraway; William R Sellers
Journal:  Nature       Date:  2019-05-08       Impact factor: 49.962

8.  Gene fusions by chromothripsis of chromosome 5q in the VCaP prostate cancer cell line.

Authors:  Inês Teles Alves; Saskia Hiltemann; Thomas Hartjes; Peter van der Spek; Andrew Stubbs; Jan Trapman; Guido Jenster
Journal:  Hum Genet       Date:  2013-04-25       Impact factor: 4.132

9.  Association of USP10 with G3BP2 Inhibits p53 Signaling and Contributes to Poor Outcome in Prostate Cancer.

Authors:  Ken-Ichi Takayama; Takashi Suzuki; Tetsuya Fujimura; Satoru Takahashi; Satoshi Inoue
Journal:  Mol Cancer Res       Date:  2018-01-29       Impact factor: 5.852

10.  The Ensembl Variant Effect Predictor.

Authors:  William McLaren; Laurent Gil; Sarah E Hunt; Harpreet Singh Riat; Graham R S Ritchie; Anja Thormann; Paul Flicek; Fiona Cunningham
Journal:  Genome Biol       Date:  2016-06-06       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.